By Eric Schweibenz
|
Jun
25
On June 17, 2020, the U.S. International Trade Commission issued press releases announcing the naming of its new Chairman and Vice-Chairman.

According to the press releases, the Commission has named Jason E. Kearns as the Chairman; and Randolph J. Stayin as the Vice Chairman. More information on this topic can be found at the Commission's website here for Chairman Kearns and here for Vice Chairman Stayin.
Share
By Eric Schweibenz and Alex Englehart
|
Jun
24
On June 19, 2020, Novartis Pharma AG of Switzerland; Novartis Pharmaceuticals Corp. of East Hanover, New Jersey; and Novartis Technology LLC of East Hanover, New Jersey (collectively, “Novartis”) filed a complaint requesting that the ITC commence an investigation pursuant to Section 337.

The complaint alleges that Regeneron Pharmaceuticals, Inc. of Tarrytown, New York (“Regeneron”) unlawfully imports into the U.S., sells for importation, and/or sells within the U.S. after importation certain pre-filled syringes for intravitreal injection, and components thereof, that infringe one or more claims of U.S. Patent No. 9,220,631.
Share

Read More

By Eric Schweibenz
|
Jun
23
On June 22, 2020, the U.S. International Trade Commission issued an update regarding its response to the evolving COVID-19 pandemic.

According to the update, the Commission has extended its COVID-19 Action Plan, enters Phase One and provides an overview of its Three-Phased Plan.  More information on this topic can be found at the Commission's website here.
Share
By Eric Schweibenz and Alex Englehart
|
Jun
22
On June 17, 2020, Hyper Ice, Inc. of Irvine, California (“Hyper Ice”) filed a complaint (part 1, part 2, and part 3) requesting that the ITC commence an investigation pursuant to Section 337.
Share

Read More

By Eric Schweibenz
|
Jul
17
On July 12, 2019, ALJ Dee Lord issued a notice of Initial Determination on Violation in Certain Microfluidic Systems, Components Thereof, and Products Containing the Same (Inv. No. 337-TA-1100).

By way of background, this investigation is based on a January 11, 2018 complaint filed by 10X Genomics, Inc. alleging violation of Section 337 by Bio-Rad Laboratories, Inc. of Hercules, California for unlawfully importing into the U.S., selling for importation, and/or selling within the U.S. after importation certain microfluidic systems, components thereof, and products containing the same that infringe one or more claims of U.S. Patent Nos. 9,644,204 (the ’204 patent), 9,689,024 (the ’024 patent), 9,695,468 (the ’468 patent), and 9,856,530 (the ’530 patent).
Share

Read More